Spark Therapeutics Inc. (ONCE)

113.00
NASDAQ : Health Technology
Prev Close 113.27
Day Low/High 112.97 / 113.40
52 Wk Low/High 34.53 / 114.20
Avg Volume 1.69M
Exchange NASDAQ
Shares Outstanding 37.75M
Market Cap 4.28B
EPS -2.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Spark Therapeutics Announces SPK-TPP1, Its First Program Targeting Neurodegenerative Disease

Spark Therapeutics Announces SPK-TPP1, Its First Program Targeting Neurodegenerative Disease

Preclinical Data Published in Science Translational Medicine Demonstrate Delay in Onset and Progression of a Form of Batten Disease

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own stock lately.

Apple Sits Out Tech Rally; S&P 500 Enjoys Record 2015 Winning Streak

Apple Sits Out Tech Rally; S&P 500 Enjoys Record 2015 Winning Streak

Apple (AAPL) shares bucked the upward trend in tech stocks after Citigroup analysts cut iPhone sales estimates on Monday.

Spark Therapeutics Trial Success Seen As Positive For Gene Therapy Sector

Spark Therapeutics Trial Success Seen As Positive For Gene Therapy Sector

The shares of Spark Therapeutics are surging after the company announced that its lead gene therapy product candidate had met its primary endpoint in a Phase 3 trial.

'Mad Money' Lightning Round: Take PPG Over Sherwin-Williams

'Mad Money' Lightning Round: Take PPG Over Sherwin-Williams

Cramer says to wait on Johnson Controls and avoid Jacobs Engineering.

Jim Cramer's 'Mad Money' Recap: 5 Groups You Once Loved but Now Hate

Jim Cramer's 'Mad Money' Recap: 5 Groups You Once Loved but Now Hate

Cramer says these five groups must be approached with caution.

Biotech Stock Mailbag: Rebounding From Hillary's Drug Tweet; Global Blood Weighs on Bluebird

Biotech Stock Mailbag: Rebounding From Hillary's Drug Tweet; Global Blood Weighs on Bluebird

Biotech columnist Adam Feuerstein answers readers' questions about health care.

5 Stocks Ready for Breakouts

5 Stocks Ready for Breakouts

These stocks look poised to break out and trade higher from current levels.

Spark Tries to Quell Investor Fears About Gene Therapy Test

Spark Tries to Quell Investor Fears About Gene Therapy Test

Spark Therapeutics provided details Thursday about changes made to a clinical trial involving the company's gene therapy, trying to calm jittery biotech investors before study results next month.

Biotech Stock Mailbag: Sarepta, Biomarin, Spark, Raptor

Biotech Stock Mailbag: Sarepta, Biomarin, Spark, Raptor

Biotech columnist Adam Feuerstein answers readers' questions about health care.

The Numbers Behind Biotech's Horrible, No Good, Awful August

The Numbers Behind Biotech's Horrible, No Good, Awful August

Among all U.S.-listed biotech stocks, regardless of market cap, only 68 companies managed to end August with higher stock prices, while 267 biotech stocks lost ground.

Biotech Stocks Get Burned This Summer, but Fall Might Bring Relief

Biotech Stocks Get Burned This Summer, but Fall Might Bring Relief

Speculative biotech stocks that were huge winners for healthcare investors earlier this year are now down significantly from their 52-week highs.

Spark Therapeutics Reports Second Quarter 2015 Results

Spark Therapeutics Reports Second Quarter 2015 Results

Confirming Guidance for Phase 3 Data Readout for SPK-RPE65 in 2015; Pipeline Advancing and Expanding

Jim Cramer: Spark Therapeutics (ONCE) Is Capable of Doing Amazing Things

Jim Cramer: Spark Therapeutics (ONCE) Is Capable of Doing Amazing Things

Spark Therapeutics (ONCE) stock is rising after Jim Cramer spoke with co-founder and CEO Jeff Marrazzo on CNBC's Mad Money show Wednesday night.

Jim Cramer's Top Takeaways: Live Nation, Spark Therapeutics, Ambarella

Jim Cramer's Top Takeaways: Live Nation, Spark Therapeutics, Ambarella

Cramer says Fitbit, Ambarella and GoPro may not be too expensive to own with their growth rates and market potential.

Jim Cramer's 'Mad Money' Recap: Road to China Is Lined With Bears and Bulls

Jim Cramer's 'Mad Money' Recap: Road to China Is Lined With Bears and Bulls

Cramer is not worried about Apple, and suggests viewers sit back and wait until the post-earnings panic subsides.

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Cramer sees a week bookended by Greece and the monthly jobs report, with many company earnings for good measure.

'Mad Money' Lightning Round: Buy, Buy, Buy Celgene; I'm a Believer

'Mad Money' Lightning Round: Buy, Buy, Buy Celgene; I'm a Believer

Cramer said Chevron's too cheap, he likes Sun Edison over Canadian Solar and wants you to buy Box.

Jim Cramer's 'Mad Money' Recap: Thanks for Nothing, Janet Yellen

Jim Cramer's 'Mad Money' Recap: Thanks for Nothing, Janet Yellen

Today the Federal Reserve told us what we already knew about the U.S. economy, Cramer says.

Bluebird Sickle Cell Gene Therapy Results Keep Getting Better

Bluebird Sickle Cell Gene Therapy Results Keep Getting Better

Six months after infusion with the Bluebird gene therapy known as LentiGlobin, almost half of the oxygen-carrying red blood cells in a single patient are normal and functioning.

Bluebird Bio First Look at Gene Therapy for Sickle Cell Disease

Bluebird Bio First Look at Gene Therapy for Sickle Cell Disease

After four and a half months of follow-up, the sickle cell patient's blood contained 24% 'marked' beta globin, a measure of normally functioning hemoglobin, Bluebird announced Thursday.

TheStreet Quant Rating: D+ (Sell)